SCHEMBL8404664

SCHEMBL8404664

NCc1ccc(C(=O)NCCO)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 1/20 0.61
▸ HDAC6 Q9UBN7 1/20 0.61
▸ NCOR2 Q9Y618 1/20 0.61
▸ MCHR1 Q99705 2/20 0.59
▸ CA12 O43570 2/20 0.55
▸ CA1 P00915 2/20 0.55
▸ CA2 P00918 2/20 0.55
▸ CA9 Q16790 2/20 0.55
▸ CA14 Q9ULX7 1/20 0.55
▸ SPHK2 Q9NRA0 2/20 0.55
▸ SPHK1 Q9NYA1 1/20 0.55
▸ POLB P06746 2/20 0.53
▸ HPGD P15428 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ MMP13 P45452 1/20 0.53
▸ LOXL2 Q9Y4K0 4/20 0.52
▸ LOX P28300 1/20 0.52
▸ CYP1A2 P05177 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ NFKB1 P19838 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11907494 0.98 HDAC3 (0.59) HDAC3HDAC6NCOR2MCHR1CA12
SCHEMBL23254636 0.87 CYP1A2 (0.68) HDAC3HDAC6NCOR2MCHR1CA12
SCHEMBL620074 0.86 POLB (0.66) HDAC6CA12CA1CA2CA9
SCHEMBL8234410 0.85 HDAC3 (0.61) HDAC3HDAC6NCOR2MCHR1CA2
SCHEMBL12913509 0.85 MAOB (0.70) CA12CA1CA2CA9CA14
SCHEMBL8404683 0.84 LMNA (0.52) HDAC3HDAC6NCOR2MCHR1CA12
SCHEMBL8404711 0.84 SMN1; SMN2 (0.55) HDAC3HDAC6NCOR2MCHR1CA2
SCHEMBL20031964 0.84 HDAC3 (0.59) HDAC3HDAC6NCOR2MCHR1CA12
SCHEMBL5095811 0.83 CFD (0.57) HDAC3HDAC6SPHK2SPHK1POLB
SCHEMBL13009911 0.82 HDAC6 (0.68) HDAC3HDAC6NCOR2MCHR1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017200984-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T GLOBAL INC. (US) 2017-11-23 — — WO disclosed
US-9328085-B2 Heterocyclic compounds and expansion agents for hematopoietic stem cells NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-05-03 — — US disclosed
US-9328085-B2 Heterocyclic compounds and expansion agents for hematopoietic stem cells NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-05-03 — — US disclosed
US-20130245255-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-09-19 — — US disclosed
US-20130245255-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-09-19 — — US disclosed
US-20120128640-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2012-05-24 — — US disclosed
US-20120128640-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2012-05-24 — — US disclosed
US-5576174-A CATALYSIS OF ALDOLIZATION REACTION WITH ANTIBODIES AND AMINES THE SCRIPPS RESEARCH INSTITUTE (US) 1996-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245255-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS HCLS1, RUNX1, RCC1 HDAC3 116/4885HDAC6 355/4885NCOR2 1457/4885
US-20120128640-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS HCLS1, RUNX1, RCC1 HDAC3 116/4885HDAC6 355/4885NCOR2 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback